MAP2K7 and melanoma: The phase 2 NeoCombi trial enrolled 35 patients with BRAF V600-mutated melanoma with clinically detectable lymph nodes to receive combination BRAF/MEK inhibition with dabrafenib/trametinib for 12 weeks prior to surgery.